Drug Trial News

RSS

MSK begins CAR T cell clinical trial for children with relapsed or treatment-resistant ALL

Researchers from Memorial Sloan Kettering Cancer Center are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

12 Apr 2015

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics Limited (ASX: BNO, OTCQX: BNOEF) today announced that it will present a poster with new data on the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the 7th Asian Oncology Summit being held from April 10-12, 2015 in Shanghai, China.

10 Apr 2015

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%.

9 Apr 2015

Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

Shire plc today announced that the 13-week Phase 2 IMAGO trial of its investigational compound SHP625 (LUM001) did not meet the primary or secondary endpoints in the study of 20 pediatric patients with Alagille syndrome (ALGS), a rare, life-threatening genetic disorder that presents with chronic cholestasis (accumulation of bile acids in the liver) and severe pruritus (itching).

9 Apr 2015

Phase 1 clinical trial: Anti-HIV antibody significantly decreases HIV levels

A single infusion of an experimental anti-HIV antibody called 3BNC117 resulted in significantly decreased HIV levels that persisted for as long as 28 days in HIV-infected individuals, according to Phase 1 clinical trial findings published online today in Nature.

8 Apr 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26.

8 Apr 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

Rhythm, a biopharmaceutical company, and Actavis plc, a leading global pharmaceutical company, announced today the initiation of a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Rhythm's ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes.

8 Apr 2015

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.

8 Apr 2015

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.

7 Apr 2015

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.

6 Apr 2015

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer.

2 Apr 2015

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

A live vaccine based on the "Vesicular Stomatitis Virus" (VSV) has yielded highly promising results for the rapid development of an effective vaccine against the Ebola virus. This vaccine would only need to be injected once for long-lasting immunoprotection.

2 Apr 2015

International researchers examine efficacy of rVSV-ZEBOV-GP Ebola vaccine

The World Health Organisation declared the Ebola virus outbreak a public health emergency in August 2014; since then the development of vaccines against Ebola virus has been fast tracked.

2 Apr 2015

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

The Honourable Rona Ambrose, Minister of Health, and Canada's Chief Public Health Officer, Dr. Gregory Taylor, today welcomed the news of promising trial outcomes of Canada's VSV-EBOV Ebola vaccine. The results of several studies and trials bring the world closer to ending this global outbreak through the provision of a commercially available vaccine.

2 Apr 2015

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

Argos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis technology platform, today announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company’s investigational fully personalized immunotherapy for HIV.

2 Apr 2015

World-first human clinical trials for Hendra virus to begin this month

An antibody manufactured at The University of Queensland will be used in world-first human Hendra virus clinical trials starting this month.

1 Apr 2015

Emmaus Life Sciences presents Phase 3 clinical trial of PGLG treatment for sickle cell disease

Emmaus Life Sciences, Inc., a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases today announced that data from the Company’s Phase 3 clinical trial of its pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, will be presented, during the 9th Annual Sickle Cell Disease Research and Educational Symposium and 38th National Sickle Cell Disease Scientific Meeting.

1 Apr 2015

PAION initiates Remimazolam Phase 3 trial in patients undergoing colonoscopy

PAION, Inc., a wholly owned subsidiary of PAION AG, today announced the initiation of a U.S. Phase 3 clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing colonoscopy.

31 Mar 2015

Cardio3 BioSciences announces successful completion of futility analysis for C-Cure

Cardio3 BioSciences, a leader in engineered cell therapy treatments, today announced the successful completion of a futility analysis for C-Cure, its lead cell therapy for congestive heart failure, currently being evaluated in a Phase III clinical trial in Europe and Israel (CHART-1).

31 Mar 2015

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

US-Australian drug discovery company, Novogen Ltd, and its subsidiary, CanTx, Inc., and Yale University, on March 27 released pre-clinical data on experimental anti-cancer drug, Cantrixil. The data was presented as an oral presentation by Professor Gil Mor MD PhD of Yale Medical School to the 62nd Annual Scientific Meeting of the Society of Reproductive Investigation in San Francisco, CA.

30 Mar 2015

Drug Trial News

MSK begins CAR T cell clinical trial for children with relapsed or treatment-resistant ALL

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Phase 2 IMAGO trial of SHP625 fails to meet primary endpoints in pediatric patients with ALGS

Phase 1 clinical trial: Anti-HIV antibody significantly decreases HIV levels

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Rhythm, Actavis announce initiation of relamorelin Phase 2b trial for treatment of diabetic gastroparesis

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Personalized cancer vaccines can be used to marshal powerful immune response

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

VSV-based vaccine yields promising results for rapid development of effective Ebola vaccine

International researchers examine efficacy of rVSV-ZEBOV-GP Ebola vaccine

Canada's VSV-EBOV Ebola vaccine proves safe, effective in Phase 1 clinical trial

NIH approves $6.6 million in funding for Phase 2a adult eradication study of Argos' AGS-004

World-first human clinical trials for Hendra virus to begin this month

Emmaus Life Sciences presents Phase 3 clinical trial of PGLG treatment for sickle cell disease

PAION initiates Remimazolam Phase 3 trial in patients undergoing colonoscopy

Cardio3 BioSciences announces successful completion of futility analysis for C-Cure

Cantrixil proves highly effective at killing human ovarian stem cells in pre-clinical study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News